The State of Overmedication in Borderline Personality Disorder: Interpersonal and Structural Factors

• Published in: Current treatment options in psychiatry 2022-03, Vol.9 (1), p.1-13
• Main Authors: Shapiro-Thompson, Rosa, Fineberg, Sarah K.
• Format: Article
• Language: English
• Subjects: Borderline personality disorder; Medicine; Medicine & Public Health; Neurology; Personality disorders; Personality Disorders (M Zimmerman; Psychiatry; Section Editor; Topical Collection on Personality Disorders
• ISSN: 2196-3061; 2196-3061
• DOI: 10.1007/s40501-021-00255-x

Purpose of Review This review paper describes the state of prescribing practice in Borderline Personality Disorder (BPD), wherein medications are prescribed far more than either evidence or practice guidelines would recommend. First, we describe the frequencies of medication use and polypharmacy in people with BPD. Recent Findings In subsequent sections, we elaborate two main categories of factors that lead to overmedication of people with BPD: the interpersonally mediated and the structural. We consider interpersonally mediated factors to arise from communications of patients in distress and the well-meaning efforts of their prescribers to provide relief for certain overwhelming affective states. We are particularly focused on patterns of countertransference in prescribing that are directly linked to specific aspects of BPD pathology. We consider structural factors to arise from the complexities of medical and medicolegal systems and the contemporary patterns of financing medical care; we postulate that these complexities often compel prescribers to start medications, with associated disincentives for decreasing or discontinuing those medications over time. Summary More research is needed to understand how to best use medications in BPD, for example in targeted combination with psychotherapeutic and psychosocial interventions. However, current practice often departs markedly from the evidence. We recommend the dissemination of accessible, generalist BPD-treatment models in outpatient and inpatient practice; increased early detection of BPD; and increased diagnostic disclosure. We also recommend for individual providers and systems to implement prospective treatment plans that draw from BPD-specific psychosocial models. This approach can employ tiers of interventions to minimize reactive prescribing by anticipating high affect and offering BPD patients steadily empathic evidence-supported care.